Kura Oncology Inc. (NASDAQ:KURA) and Neuralstem Inc. (NASDAQ:CUR) compete against each other in the Biotechnology sector. We will contrast them and contrast their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Table 1 highlights Kura Oncology Inc. and Neuralstem Inc.s gross revenue, earnings per share and valuation.

Profitability

Table 2 demonstrates the return on assets, return on equity and net margins of Kura Oncology Inc. and Neuralstem Inc.

Risk & Volatility

A beta of 2.5 shows that Kura Oncology Inc. is 150.00% more volatile than Standard & Poors 500. In other hand, Neuralstem Inc. has beta of 1.94 which is 94.00% more volatile than Standard & Poors 500.

Liquidity

The current Quick Ratio of Kura Oncology Inc. is 13.8 while its Current Ratio is 13.8. Meanwhile, Neuralstem Inc. has a Current Ratio of 3.8 while its Quick Ratio is 3.8. Kura Oncology Inc. is better positioned to pay off its short-term and long-term debts than Neuralstem Inc.

Analyst Ratings

The following table shown below contains the ratings and recommendations for Kura Oncology Inc. and Neuralstem Inc.

Kura Oncology Inc.s consensus price target is $22, while its potential upside is 58.96%.

Institutional & Insider Ownership

Kura Oncology Inc. and Neuralstem Inc. has shares owned by institutional investors as follows: 70.8% and 4.9%. Insiders owned roughly 0.8% of Kura Oncology Inc.s shares. Insiders Comparatively, owned 1% of Neuralstem Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Kura Oncology Inc. had bullish trend while Neuralstem Inc. had bearish trend.

Summary

Kura Oncology Inc. beats Neuralstem Inc. on 10 of the 11 factors.

Kura Oncology, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The companys lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, lower risk myelodysplastic syndromes, and chronic myelomonocytic leukemia. It also develops KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment for patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in La Jolla, California.

Neuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The companys stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Here is the original post:
Comparing of Kura Oncology Inc. (KURA) and Neuralstem Inc. (NASDAQ:CUR) - MS Wkly